Advertisement

PharmacoEconomics

, Volume 33, Issue 11, pp 1137–1154 | Cite as

Can The EQ-5D Detect Meaningful Change? A Systematic Review

  • Nalin PayakachatEmail author
  • Mir M. Ali
  • J. Mick Tilford
Systematic Review

Abstract

Background

The EQ-5D is one of the most frequently used, generic, preference-based instruments for measuring the health utilities of patients in economic evaluations. It is recommended for health technology assessment by the National Institute for Health and Clinical Excellence. Because the EQ-5D plays such an important role in economic evaluations, useful information on its responsiveness to detect meaningful change in health status is required.

Objective

This study systematically reviewed and synthesized evidence on the responsiveness of the EQ-5D to detect meaningful change in health status for clinical research and economic evaluations.

Methods

We searched the EuroQol website, PubMed, PsychINFO, and EconLit databases to identify studies published in English from the inception of the EQ-5D until August 15, 2014 using keywords that were related to responsiveness. Studies that used only the EQ-VAS were excluded from the final analysis. Narrative synthesis was conducted to summarize evidence on the responsiveness of the EQ-5D by conditions or physiological functions.

Results

Of 1401 studies, 145 were included in the narrative synthesis and categorized into 19 categories for 56 conditions. The EQ-5D was found to be responsive in 25 conditions (45 %) with the magnitude of responsiveness varying from small to large depending on the condition. There was mixed evidence of responsiveness in 27 conditions (48 %). Only four conditions (7 %) (i.e., alcohol dependency, schizophrenia, limb reconstruction, and hearing impairment) were identified where the EQ-5D was not responsive.

Conclusion

The EQ-5D is an appropriate measure for economic evaluation and health technology assessment in conditions where it has demonstrated evidence of responsiveness. In conditions with mixed evidence of responsiveness, researchers should consider using the EQ-5D with other condition-specific measures to ensure appropriate estimates of effectiveness. These conditions should be a main focus for future research using the new EQ-5D version with five response levels.

Keywords

Health Technology Assessment Standardize Response Means Population Weight External Anchor Responsiveness Information 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

AUC

Area under the curve

AUROC

Area under the receiver-operating characteristic curve

COPD

Chronic obstructive pulmonary disease

CSM

Condition-specific measures

EQ-5D 5L

EuroQol-5 dimension 5 level descriptive system

EQ-5D

EuroQol-5 dimension 3 level descriptive system

EQ-VAS

EuroQol-visual analogue scale

ES

Effect size

EULAR

European League against Rheumatism

HRQL

Health-related quality of life

HUI

Health Utilities Index

HUI3

Health Utilities Index Mark 3

NICE

National Institute for Health and Clinical Excellence

NYHA

New York Heart Association class

QALY

Quality-adjusted life year

SF-6D

Short-Form-6 dimension

SRM

Standardized response means

TTO

Time trade-off

WOMAC

Western Ontario and McMaster Universities Osteoarthritis Index

Notes

Acknowledgements

No funding has been received for conducting and preparing this manuscript.

Conflicts of interest

None

Authors’ contributions

NP: study rationale and design, literature selection, quality assessment of studies, data extraction, evidence synthesis, interpretation and reflection, writing and reviewing of the manuscript, guarantor of the study. MMA: literature search, literature selection, data extraction, quality assessment of studies, writing of the manuscript. JMT: study rationale and design, interpretation and reflection, writing and reviewing of the manuscript.

References

  1. 1.
    Weinstein MC, Skinner JA. Comparative effectiveness and health care spending–implications for reform. N Engl J Med. 2010;362(5):460–5.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    NICE. Guide to the methods of technology appraisal 2013. National Institute for Health and Care Excellence. 2013. http://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf. Accessed 15 Nov 2014.
  3. 3.
    Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276(15):1253–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.PubMedCrossRefGoogle Scholar
  6. 6.
    Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42(9):851–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, Denton M, Boyle M. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care. 2002;40(2):113–28.PubMedCrossRefGoogle Scholar
  8. 8.
    Oemar M, Oppe M. EQ-5D-3L User Guide. EuroQol Group. 2013. http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-3L_UserGuide_2013_v5.0_October_2013.pdf. Accessed 15 Nov 2014.
  9. 9.
    Gray AM, Clarke P, Wolstenholme J, Wordsworth S. Measuring, valuing, and analysing health outcomes. In: Gray AM, Clarke P, Wolstenholme J, Wordsworth S, editors. Applied methods of cost-effectiveness analysis in healthcare. New York: Oxford University Press; 2011. p. 83–118.Google Scholar
  10. 10.
    Szende A, Oppe M, Devlin N. EQ-5D value sets: Inventory, comparative review and user guide. EuroQol Group Monographs, vol 2. Dordrecht, The Netherlands: Springer; 2007.Google Scholar
  11. 11.
    Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    EuroQol Group. EQ-5D-5L Value Sets. EuroQol Research Foundation. 2014. http://www.euroqol.org/about-eq-5d/valuation-of-eq-5d/eq-5d-5l-value-sets.html. Accessed 15 Nov 2014.
  13. 13.
    Brazier J, Connell J, Papaioannou D, Mukuria C, Mulhern B, Peasgood T, Jones ML, Paisley S, O’Cathain A, Barkham M, Knapp M, Byford S, Gilbody S, Parry G. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technol Assess. 2014;18(34):11–19 (vii-viii, xiii-xxv, 1188).CrossRefGoogle Scholar
  14. 14.
    Yang Y, Brazier J, Longworth L. EQ-5D in skin conditions: an assessment of validity and responsiveness. Eur J Health Econ. 2014. [Epub ahead of print].Google Scholar
  15. 15.
    Davies N, Gibbons E, Mackintosh A, Fitzpatrick R. A structured review of patient-reported outcome measures for women with breast cancer. Patient-reported Outcome Measurement Group, Department of Public Health, University of Oxford. 2009. http://phi.uhce.ox.ac.uk/pdf/CancerReviews/PROMs_Oxford_BreastCancer_012011.pdf. Accessed 15 Nov 2014.
  16. 16.
    Pickard AS, Wilke C, Jung E, Patel S, Stavem K, Lee TA. Use of a preference-based measure of health (EQ-5D) in COPD and asthma. Respir Med. 2008;102(4):519–36.PubMedCrossRefGoogle Scholar
  17. 17.
    Tordrup D, Mossman J, Kanavos P. Responsiveness of the EQ-5D to clinical change: is the patient experience adequately represented? Int J Technol Assess Health Care. 2014;30(1):10–9.PubMedCrossRefGoogle Scholar
  18. 18.
    EuroQol Group. EQ-5D References - Reference Search. EuroQol Research Foundation. 2014. http://www.euroqol.org/eq-5d-references/reference-search.html. Accessed 15 Nov 2014.
  19. 19.
    Walters SJ. Quality of life outcomes in clinical trials and health-care evaluation: a practical guide to analysis and interpretation. Chichester: Wiley; 2009.CrossRefGoogle Scholar
  20. 20.
    Hays RD, Revicki DA. Reliability and validity (including responsiveness). In: Fayers PM, Hays RD, editors. Assessing quality of life in clinical trials. 2nd ed. New York: Oxford University Press; 2005. p. 25–39.Google Scholar
  21. 21.
    Cohen J. A power primer. Psychol Bull. 1992;112(1):155–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Simundic AM. Measures of diagnostic accuracy: basic definition. http://www.ifcc.org/ifccfiles/docs/190404200805.pdf. 2011. Accessed 15 Nov 2014.
  23. 23.
    Günther OH, Roick C, Angermeyer MC, König HH. Responsiveness of EQ-5D utility indices in alcohol-dependent patients. Drug Alcohol Depend. 2008;92(1–3):291–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Essex HN, White IR, Khadjesari Z, Linke S, McCambridge J, Murray E, Parrott S, Godfrey C. Quality of life among hazardous and harmful drinkers: EQ-5D over a 1-year follow-up period. Qual Life Res. 2014;23(2):733–43.PubMedCrossRefGoogle Scholar
  25. 25.
    Papaioannou D, Brazier J, Parry G. How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review. Value Health. 2011;14(6):907–20.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Burton M, Walters SJ, Saleh M, Brazier JE. An evaluation of patient-reported outcome measures in lower limb reconstruction surgery. Qual Life Res. 2012;21(10):1731–43.PubMedCrossRefGoogle Scholar
  27. 27.
    Yang Y, Longworth L, Brazier J. An assessment of validity and responsiveness of generic measures of health-related quality of life in hearing impairment. Qual Life Res. 2013;22(10):2813–28.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Bouwmans C, van der Kolk A, Oppe M, Schawo S, Stolk E, van Agthoven M, Buitelaar J, van Roijen L. Validity and responsiveness of the EQ-5D and the KIDSCREEN-10 in children with ADHD. Eur J Health Econ. 2014;15(9):967–77.PubMedCrossRefGoogle Scholar
  29. 29.
    Kiessling A, Henriksson P. Time trends of chest pain symptoms and health related quality of life in coronary artery disease. Health Qual Life Outcomes. 2007;5:13.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Schweikert B, Hahmann H, Leidl R. Validation of the EuroQol questionnaire in cardiac rehabilitation. Heart. 2006;92(1):62–7.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Eurich DT, Johnson JA, Reid KJ, Spertus JA. Assessing responsiveness of generic and specific health related quality of life measures in heart failure. Health Qual Life Outcomes. 2006;4:89.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Kaplan RM, Tally S, Hays RD, Feeny D, Ganiats TG, Palta M, Fryback DG. Five preference-based indexes in cataract and heart failure patients were not equally responsive to change. J Clin Epidemiol. 2011;64(5):497–506.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Pickard AS, Johnson JA, Feeny DH. Responsiveness of generic health-related quality of life measures in stroke. Qual Life Res. 2005;14(1):207–19.PubMedCrossRefGoogle Scholar
  34. 34.
    Hunger M, Sabariego C, Stollenwerk B, Cieza A, Leidl R. Validity, reliability and responsiveness of the EQ-5D in German stroke patients undergoing rehabilitation. Qual Life Res. 2012;21(7):1205–16.PubMedCrossRefGoogle Scholar
  35. 35.
    Nosyk B, Sun H, Guh DP, Oviedo-Joekes E, Marsh DC, Brissette S, Schechter MT, Anis AH. The quality of eight health status measures were compared for chronic opioid dependence. J Clin Epidemiol. 2010;63(10):1132–44.PubMedCrossRefGoogle Scholar
  36. 36.
    Mulhern B, Mukuria C, Barkham M, Knapp M, Byford S, Soeteman D, Brazier J. Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D. Br J Psychiatry. 2014;205(3):236–43.PubMedCrossRefGoogle Scholar
  37. 37.
    Peasgood T, Brazier J, Papaioannou D. A systematic review of the validity and responsiveness of EQ-5D and SF-6D for depression and anxiety. The University of Sheffield, UK, White Rose Research Online. http://eprints.whiterose.ac.uk/74659/1/12.15.pdf. Accessed 15 Nov 2014.
  38. 38.
    Sonntag M, Konnopka A, Leichsenring F, Salzer S, Beutel ME, Herpertz S, Hiller W, Hoyer J, Joraschky P, Nolting B, Pöhlmann K, Stangier U, Strauss B, Willutzki U, Wiltink J, Leibing E, König HH. Reliability, validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with social phobia. Health Qual Life Outcomes. 2013;11:215. doi: 10.1186/1477-7525-11-215.:215-11.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Brettschneider C, König HH, Herzog W, Kaufmann C, Schaefert R, Konnopka A. Validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with somatoform disorders. Health Qual Life Outcomes. 2013;11:3.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Harrison MJ, Davies LM, Bansback NJ, McCoy MJ, Verstappen SM, Watson K. Symmons DP; British Society for Rheumatology Biologics Register Control Centre Consortium. The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. Qual Life Res. 2009;18(9):1195–205.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Hagel S, Lindqvist E, Petersson IF, Nilsson JÅ, Bremander A. Validation of outcome measurement instruments used in a multidisciplinary rehabilitation intervention for patients with chronic inflammatory arthritis: linking of the International Classification of Functioning, Disability and Health, construct validity and responsiveness to change. J Rehabil Med. 2011;43(5):411–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Gaujoux-Viala C, Rat AC, Guillemin F, Flipo RM, Fardellone P, Bourgeois P, Fautrel B. Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohort. Ann Rheum Dis. 2012;71(9):1478–83.PubMedCrossRefGoogle Scholar
  43. 43.
    Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol. 1997;36(5):551–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Eversden L, Maggs F, Nightingale P, Jobanputra P. A pragmatic randomized controlled trial of hydrotherapy and land exercises on overall well being and quality of life in rheumatoid arthritis. BMC Musculoskelet Disord. 2007;8:23.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Linde L, Sørensen J, Ostergaard M, Hørslev-Petersen K, Hetland ML. Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis. J Rheumatol. 2008;35(8):1528–37.PubMedGoogle Scholar
  46. 46.
    Buitinga L, Braakman-Jansen LM, Taal E, Kievit W, Visser H, van Riel PL, van de Laar MA. Comparative responsiveness of the EuroQol-5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry. Arthritis Care Res (Hoboken). 2012;64(6):826–32.CrossRefGoogle Scholar
  47. 47.
    Haywood KL, Garratt AM, Dziedzic K, Dawes PT. Generic measures of health-related quality of life in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford). 2002;41(12):1380–7.CrossRefGoogle Scholar
  48. 48.
    Conner-Spady B, Suarez-Almazor ME. Variation in the estimation of quality-adjusted life-years by different preference-based instruments. Med Care. 2003;41(7):791–801.PubMedCrossRefGoogle Scholar
  49. 49.
    Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. A comparison of the responsiveness of different generic health status measures in patients with asthma. Qual Life Res. 2003;12(5):555–63.PubMedCrossRefGoogle Scholar
  50. 50.
    Petrillo J, van Nooten F, Jones P, Rutten-van Mölken M. Utility estimation in chronic obstructive pulmonary disease: a preference for change? Pharmacoeconomics. 2011;29(11):917–32.PubMedCrossRefGoogle Scholar
  51. 51.
    Paterson C, Langan CE, McKaig GA, Anderson PM, Maclaine GD, Rose LB, Walker SJ, Campbell MJ. Assessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQol (EQ-5D). Qual Life Res. 2000;9(5):521–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Jenkinson C, Gray A, Doll H, Lawrence K, Keoghane S, Layte R. Evaluation of index and profile measures of health status in a randomized controlled trial. Comparison of the Medical Outcomes Study 36-Item Short Form Health Survey, EuroQol, and disease specific measures. Med Care. 1997;35(11):1109–18.PubMedCrossRefGoogle Scholar
  53. 53.
    MacDonagh RP, Cliff AM, Speakman MJ, O’Boyle PJ, Ewings P, Gudex C. The use of generic measures of health-related quality of life in the assessment of outcome from transurethral resection of the prostate. Br J Urol. 1997;79(3):401–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Krahn M, Bremner KE, Tomlinson G, Ritvo P, Irvine J, Naglie G. Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Qual Life Res. 2007;16(3):509–22.PubMedCrossRefGoogle Scholar
  55. 55.
    Kimman ML, Dirksen CD, Lambin P, Boersma LJ. Responsiveness of the EQ-5D in breast cancer patients in their first year after treatment. Health Qual Life Outcomes. 2009;7:11. doi: 10.1186/1477-7525-7-11.:11-17.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Lee CF, Luo N, Ng R, Wong NS, Yap YS, Lo SK, Chia WK, Yee A, Krishna L, Wong C, Goh C, Cheung YB. Comparison of the measurement properties between a short and generic instrument, the 5-level EuroQoL Group’s 5-dimension (EQ-5D-5L) questionnaire, and a longer and disease-specific instrument, the Functional Assessment of Cancer Therapy-Breast (FACT-B), in Asian breast cancer patients. Qual Life Res. 2013;22(7):1745–51.PubMedCrossRefGoogle Scholar
  57. 57.
    Krabbe PF, Peerenboom L, Langenhoff BS, Ruers TJ. Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res. 2004;13(7):1247–53.PubMedCrossRefGoogle Scholar
  58. 58.
    Kvam AK, Fayers PM, Wisloff F. Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. Eur J Haematol. 2011;87(4):330–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Davis S, Wailoo A. A review of the psychometric performance of the EQ-5D in people with urinary incontinence. Health Qual Life Outcomes. 2013;11:20.PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Kunz S. Psychometric properties of the EQ-5D in a study of people with mild to moderate dementia. Qual Life Res. 2010;19(3):425–34.PubMedCrossRefGoogle Scholar
  61. 61.
    PD Med Collaborative Group. Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196–205.CrossRefGoogle Scholar
  62. 62.
    Luo N, Ng WY, Lau PN, Au WL, Tan LC. Responsiveness of the EQ-5D and 8-item Parkinson’s Disease Questionnaire (PDQ-8) in a 4-year follow-up study. Qual Life Res. 2010;19(4):565–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Schrag A, Spottke A, Quinn NP, Dodel R. Comparative responsiveness of Parkinson’s disease scales to change over time. Mov Disord. 2009;24(6):813–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Langfitt JT, Vickrey BG, McDermott MP, Messing S, Berg AT, Spencer SS, Sperling MR, Bazil CW, Shinnar S. Validity and responsiveness of generic preference-based HRQOL instruments in chronic epilepsy. Qual Life Res. 2006;15(5):899–914.PubMedCrossRefGoogle Scholar
  65. 65.
    Janssen MF, Lubetkin EI, Sekhobo JP, Pickard AS. The use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitus. Diabet Med. 2011;28(4):395–413.PubMedCrossRefGoogle Scholar
  66. 66.
    Riazi A, Cano SJ, Cooper JM, Bradley JL, Schapira AH, Hobart JC. Coordinating outcomes measurement in ataxia research: do some widely used generic rating scales tick the boxes? Mov Disord. 2006;21(9):1396–403.PubMedCrossRefGoogle Scholar
  67. 67.
    Godil SS, Parker SL, Zuckerman SL, Mendenhall SK, McGirt MJ. Accurately measuring outcomes after surgery for adult Chiari I malformation: determining the most valid and responsive instruments. Neurosurgery. 2013;72(5):820–7 discussion 827.PubMedCrossRefGoogle Scholar
  68. 68.
    Sagberg LM, Jakola AS, Solheim O. Quality of life assessed with EQ-5D in patients undergoing glioma surgery: what is the responsiveness and minimal clinically important difference? Qual Life Res. 2014;23(5):1427–34.PubMedCrossRefGoogle Scholar
  69. 69.
    Pink J, Petrou S, Williamson E, Williams M, Lamb SE. Properties of patient-reported outcome measures in individuals following acute whiplash injury. Health Qual Life Outcomes. 2014;12:38. doi: 10.1186/1477-7525-12-38.:38-12.PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    Tidermark J, Bergström G, Svensson O, Törnkvist H, Ponzer S. Responsiveness of the EuroQol (EQ 5-D) and the SF-36 in elderly patients with displaced femoral neck fractures. Qual Life Res. 2003;12(8):1069–79.PubMedCrossRefGoogle Scholar
  71. 71.
    Tidermark J, Bergström G. Responsiveness of the EuroQol (EQ-5D) and the Nottingham Health Profile (NHP) in elderly patients with femoral neck fractures. Qual Life Res. 2007;16(2):321–30.PubMedCrossRefGoogle Scholar
  72. 72.
    Frihagen F, Grotle M, Madsen JE, Wyller TB, Mowinckel P, Nordsletten L. Outcome after femoral neck fractures: a comparison of Harris Hip Score, Eq-5d and Barthel Index. Injury. 2008;39(10):1147–56.PubMedCrossRefGoogle Scholar
  73. 73.
    Godil SS, Parker SL, Zuckerman SL, Mendenhall SK, McGirt MJ. Accurately measuring the quality and effectiveness of cervical spine surgery in registry efforts: determining the most valid and responsive instruments. Spine J. 2013;. doi: 10.1016/j.spinee.2013.07.444.Google Scholar
  74. 74.
    Olerud P, Tidermark J, Ponzer S, Ahrengart L, Bergström G. Responsiveness of the EQ-5D in patients with proximal humeral fractures. J Shoulder Elbow Surg. 2011;20(8):1200–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Parsons N, Griffin XL, Achten J, Costa ML. Outcome assessment after hip fracture: is EQ-5D the answer? Bone Joint Res. 2014;3(3):69–75.PubMedCentralPubMedCrossRefGoogle Scholar
  76. 76.
    Zampelis V, Ornstein E, Franzén H, Atroshi I. A simple visual analog scale for pain is as responsive as the WOMAC, the SF-36, and the EQ-5D in measuring outcomes of revision hip arthroplasty. Acta Orthop. 2014;85(2):128–32.PubMedCentralPubMedCrossRefGoogle Scholar
  77. 77.
    Ostendorf M, van Stel HF, Buskens E, Schrijvers AJ, Marting LN, Verbout AJ, Dhert WJ. Patient-reported outcome in total hip replacement. A comparison of five instruments of health status. J Bone Joint Surg Br. 2004;86(6):801–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Goodwin PC, Ratcliffe J, Morris J, Morrissey MC. Using the knee-specific Hughston Clinic Questionnaire, EQ-5D and SF-6D following arthroscopic partial meniscectomy surgery: a comparison of psychometric properties. Qual Life Res. 2011;20(9):1437–46.PubMedCrossRefGoogle Scholar
  79. 79.
    Lin FJ, Samp J, Munoz A, Wong PS, Pickard AS. Evaluating change using patient-reported outcome measures in knee replacement: the complementary nature of the EQ-5D index and VAS scores. Eur J Health Econ. 2014;15(5):489–96.PubMedCrossRefGoogle Scholar
  80. 80.
    Brazier JE, Harper R, Munro J, Walters SJ, Snaith ML. Generic and condition-specific outcome measures for people with osteoarthritis of the knee. Rheumatology (Oxford). 1999;38(9):870–7.CrossRefGoogle Scholar
  81. 81.
    Giesinger K, Hamilton DF, Jost B, Holzner B, Giesinger JM. Comparative responsiveness of outcome measures for total knee arthroplasty. Osteoarthritis Cartil. 2014;22(2):184–9.CrossRefGoogle Scholar
  82. 82.
    Dawson J, Boller I, Doll H, Lavis G, Sharp R, Cooke P, Jenkinson C. Responsiveness of the Manchester-Oxford Foot Questionnaire (MOXFQ) compared with AOFAS, SF-36 and EQ-5D assessments following foot or ankle surgery. J Bone Jt Surg Br. 2012;94(2):215–21.CrossRefGoogle Scholar
  83. 83.
    Maher AJ, Kilmartin TE. An analysis of Euroqol EQ-5D and Manchester Oxford Foot Questionnaire scores six months following podiatric surgery. J Foot Ankle Res. 2012;. doi: 10.1186/1757-1146-5-17.PubMedCentralGoogle Scholar
  84. 84.
    DeVine J, Norvell DC, Ecker E, Fourney DR, Vaccaro A, Wang J, Andersson G. Evaluating the correlation and responsiveness of patient-reported pain with function and quality-of-life outcomes after spine surgery. Spine (Phila Pa 1976). 2011;36(21 Suppl):S69–74.CrossRefGoogle Scholar
  85. 85.
    Godil SS, Parker SL, Zuckerman SL, Mendenhall SK, Glassman SD, McGirt MJ. Accurately measuring the quality and effectiveness of lumbar surgery in registry efforts: determining the most valid and responsive instruments. Spine J. 2014;14(12):2885–91.PubMedCrossRefGoogle Scholar
  86. 86.
    Solberg T, Johnsen LG, Nygaard ØP, Grotle M. Can we define success criteria for lumbar disc surgery? Estimates for a substantial amount of improvement in core outcome measures. Acta Orthop. 2013;84(2):196–201.PubMedCentralPubMedCrossRefGoogle Scholar
  87. 87.
    Staerkle RF, Villiger P. Simple questionnaire for assessing core outcomes in inguinal hernia repair. Br J Surg. 2011;98(1):148–55.PubMedCrossRefGoogle Scholar
  88. 88.
    Lee L, Mata J, Augustin BR, Carli F, Morin N, Latimer E, Feldman LS. A comparison of the validity of two indirect utility instruments as measures of postoperative recovery. J Surg Res. 2014;190(1):79–86.PubMedCrossRefGoogle Scholar
  89. 89.
    Tosh J, Brazier J, Evans P, Longworth L. A review of generic preference-based measures of health-related quality of life in visual disorders. Value Health. 2012;15(1):118–27.PubMedCentralPubMedCrossRefGoogle Scholar
  90. 90.
    Ang M, Fenwick E, Wong TY, Lamoureux E, Luo N. Utility of EQ-5D to assess patients undergoing cataract surgery. Optom Vis Sci. 2013;90(8):861–6.PubMedCrossRefGoogle Scholar
  91. 91.
    Fenwick EK, Xie J, Ratcliffe J, Pesudovs K, Finger RP, Wong TY, Lamoureux EL. The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes. Invest Ophthalmol Vis Sci. 2012;53(2):677–84. doi: 10.1167/iovs.11-8992.PubMedCrossRefGoogle Scholar
  92. 92.
    Maes IH, Joore MA, Cima RF, Vlaeyen JW, Anteunis LJ. Assessment of health state in patients with tinnitus: a comparison of the EQ-5D and HUI mark III. Ear Hear. 2011;32(4):428–35.PubMedCrossRefGoogle Scholar
  93. 93.
    Wu AW, Hanson KA, Harding G, Haider S, Tawadrous M, Khachatryan A, Pashos CL, Simpson KN. Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies. Health Qual Life Outcomes. 2013;. doi: 10.1186/1477-7525-11-42.Google Scholar
  94. 94.
    König HH, Ulshöfer A, Gregor M, von Tirpitz C, Reinshagen M, Adler G, Leidl R. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002;14(11):1205–15.PubMedCrossRefGoogle Scholar
  95. 95.
    Stark RG, Reitmeir P, Leidl R, König HH. Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. Inflamm Bowel Dis. 2010;16(1):42–51.PubMedCrossRefGoogle Scholar
  96. 96.
    Bushnell DM, Martin ML, Ricci JF, Bracco A. Performance of the EQ-5D in patients with irritable bowel syndrome. Value Health. 2006;9(2):90–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Obradovic M, Lal A, Liedgens H. Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic pain. Health Qual Life Outcomes. 2013;. doi: 10.1186/1477-7525-11-110.PubMedCentralPubMedGoogle Scholar
  98. 98.
    Barton GR, Sach TH, Avery AJ, Doherty M, Jenkinson C, Muir KR. Comparing the performance of the EQ-5D and SF-6D when measuring the benefits of alleviating knee pain. Cost Eff Resour Alloc. 2009;. doi: 10.1186/1478-7547-7-12.PubMedCentralPubMedGoogle Scholar
  99. 99.
    Chapman JR, Norvell DC, Hermsmeyer JT, Bransford RJ, DeVine J, McGirt MJ, Lee MJ. Evaluating common outcomes for measuring treatment success for chronic low back pain. Spine (Phila Pa 1976). 2011;36(21 Suppl1):S54–68.CrossRefGoogle Scholar
  100. 100.
    Campbell H, Rivero-Arias O, Johnston K, Gray A, Fairbank J, Frost H, UK MRC Spine Stabilization Trial. Responsiveness of objective, disease-specific, and generic outcome measures in patients with chronic low back pain: an assessment for improving, stable, and deteriorating patients. Spine (Phila Pa 1976). 2006;31(7):815–22.CrossRefGoogle Scholar
  101. 101.
    Soer R, Reneman MF, Speijer BL, Coppes MH, Vroomen PC. Clinimetric properties of the EuroQol-5D in patients with chronic low back pain. Spine J. 2012;12(11):1035–9.PubMedCrossRefGoogle Scholar
  102. 102.
    Aggarwal R, Wilke CT, Pickard AS, Vats V, Mikolaitis R, Fogg L, Block JA, Jolly M. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol. 2009;36(6):1209–16.PubMedCrossRefGoogle Scholar
  103. 103.
    Coast J, Peters TJ, Richards SH, Gunnell DJ. Use of the EuroQoL among elderly acute care patients. Qual Life Res. 1998;7(1):1–10.PubMedCrossRefGoogle Scholar
  104. 104.
    Holland R, Smith RD, Harvey I, Swift L, Lenaghan E. Assessing quality of life in the elderly: a direct comparison of the EQ-5D and AQoL. Health Econ. 2004;13(8):793–805.PubMedCrossRefGoogle Scholar
  105. 105.
    The measurement and valuation of health status using EQ-5D: A European perspective. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2003.Google Scholar
  106. 106.
    Feeny D. Preference-based meausres: utility and quality-adjusted life years. In: Fayers P, Hays R, editors. Assessing quality of life in clinical trials. 2nd ed. New York: Oxford University Press; 2005. p. 405–30.Google Scholar
  107. 107.
    Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics. 2000;17(1):13–35.PubMedCrossRefGoogle Scholar
  108. 108.
    Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004;13(9):873–84.PubMedCrossRefGoogle Scholar
  109. 109.
    Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27(3 Suppl):S217–32 Review.PubMedCrossRefGoogle Scholar
  110. 110.
    Grosse SD, Chaugule SS, Hay JW. Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Rev Pharmacoecon Outcomes Res. 2015;1–17. [Epub ahead of print].Google Scholar
  111. 111.
    Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes. 2006;4:70.PubMedCentralPubMedCrossRefGoogle Scholar
  112. 112.
    Streiner DL, Norman GR. Measuring change. In: Streiner DL, Norman GR, editors. Health measurement scales: A practical guide to their development and use. 4th ed. New York: Oxford University Press; 2008. p. 277–97.CrossRefGoogle Scholar
  113. 113.
    Fairclough DL. Study design and protocol development. In: Fairclough DL, editor. Design and analysis of quality of life studies in clinical trials. 2nd ed. Boca Raton: Chapman & Hall/CRC; 2010. p. 29–52.Google Scholar
  114. 114.
    Gerhards SA, Huibers MJ, Theunissen KA, de Graaf LE, Widdershoven GA, Evers SM. The responsiveness of quality of life utilities to change in depression: a comparison of instruments (SF-6D, EQ-5D, and DFD). Value Health. 2011;14(5):732–9.PubMedCrossRefGoogle Scholar
  115. 115.
    Lazarus RS. Coping theory and research: past, present, and future. Psychosom Med. 1993;55(3):234–47.PubMedCrossRefGoogle Scholar
  116. 116.
    Lazarus RS, Folkman S. Stress, appraisal and coping. New York: Springer; 1984.Google Scholar
  117. 117.
    Roesch SC, Adams L, Hines A, Palmores A, Vyas P, Tran C, Pekin S, Vaughn AA. Coping with prostate cancer: a meta-analytic review. J Behav Med. 2005;28(3):281–93.PubMedCrossRefGoogle Scholar
  118. 118.
    Wonghongkul T, Dechaprom N, Phumivichuvate L, Losawatkul S. Uncertainty appraisal coping and quality of life in breast cancer survivors. Cancer Nurs. 2006;29(3):250–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Nalin Payakachat
    • 1
    Email author
  • Mir M. Ali
    • 2
  • J. Mick Tilford
    • 1
    • 2
  1. 1.Division of Pharmaceutical Evaluation and Policy, Department of Pharmacy PracticeUniversity of Arkansas for Medical SciencesLittle RockUSA
  2. 2.Department of Health Policy and ManagementUniversity of Arkansas for Medical SciencesLittle RockUSA

Personalised recommendations